New Platform: Unbridle Your Potential | Boehringer Ingelheim US
Read more on the Boehringer Ingelheim brand platform: Unbridle Your Potential, aimed at providing support and leadership for the equine industry.
Search
Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
Click here to read more about how the use of JARDIANCE reduced the risk of kidney disease progression in adults with established CVD and T2D.
Planting Trees to Help Care for the Environment
Planting Trees to Help Care for the Environment
directions_from_bradley.pdf
directions_from_westchester.pdf
directions_from_newark.pdf
directions_from_jfk.pdf
directions_from_laguardia.pdf
Public Health Cost from AF.pdf
Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US
Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.
How we Support Grass Roots Innovation
How we Support Grass Roots Innovation
Moving to Germany
We started in Germany, but we have offices all over the world.
Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.
Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.
Jardiance® (empagliflozin) Reduces Risk for CV Death | BI US
Analyses show risk reductions were consistent across age groups for CV outcomes with JARDIANCE compared with placebo. View ISI, PI & Med Guide.
Partnering Purpose: BI Gives Back | Boehringer Ingelheim US
Hear from Sheila Denton, Senior Vice President, General Counsel and Corporate Secretary, on the importance of giving back to our communities.
How Boehringer Ingelheim US Helps Injured Veterans | Boehringer Ingelheim US
Read more on how Boehringer Ingelheim supports injured veterans in making a fresh start through the use of service dogs, with the Warrior Canine Connection.
Expanded Access Programs
Expanded Access Programs
Coliform Mastitis: the facts to know | Boehringer Ingelheim US
Click here to learn more about different management practices that can help you to improve your dairy herd's bottom line and productivity.
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
Company History | Corporate Profile | Boehringer Ingelheim US
Click here to watch our video on the history of Boehringer Ingelheim, founded by Albert Boehringer in 1885.
Translating Human Pharma Science into Animal Health Innovation
Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
Chronic Kidney Disease
Chronic Kidney Disease
Our Partnering Approach in Animal Health
Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.
Jardiance® (empagliflozin) Meets Endpoint Reducing CV Death | BI US
BI announces results from the EMPEROR-Reduced trial with heart failure with reduced ejection fraction, with & without diabetes. View ISI, PI and Med Guide.
Reducing Stress in Horses – With Music
Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".